Zantac’s Original Maker Halts Shipping on Carcinogen Concern
- Glaxo will recall popular stomach drug in India, Hong Kong
- Health officials worldwide investigating carcinogen in Zantac
This article is for subscribers only.
GlaxoSmithKline Plc, the original branded maker of Zantac, halted global distribution of the popular stomach medicine, adding momentum to actions aimed at stopping access to drugs that are tainted with a potential human carcinogen.
Glaxo will also recall the drug in India, where it’s known as Zinetac, and Hong Kong. The recalled medicine is made with an active ingredient from two India-based suppliers, Dr. Reddy’s Laboratories Ltd. and Saraca Laboratories Ltd., Kristen Neese, a spokeswoman for Glaxo, said in an email Wednesday.